New hive drug shows promise in Head-to-Head trial against XOLAIR

NCT ID NCT04976192

Completed Disease control Sponsor: Teva Pharmaceuticals USA Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times

Summary

This study tested whether a new medicine, TEV-45779, works as well as the approved drug XOLAIR for people with chronic hives (itchy welts) that don't get better with standard allergy pills. About 608 adults took part. The main goal was to see how much itching improved after 12 weeks. Results help doctors understand if TEV-45779 is a good alternative for controlling this condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC URTICARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

10004

Salt Lake City, Utah, 84117, United States
10005

Miami, Florida, 33014, United States
10006

Kissimmee, Florida, 34744, United States
10007

Troy, Michigan, 48084, United States
10008

Bakersfield, California, 93301, United States
10009

Tampa, Florida, 33613, United States
10012

Coral Gables, Florida, 33134, United States
10014

Maitland, Florida, 32751, United States
Site 10001

Clearwater, Florida, 33765, United States

Conditions

Explore the condition pages connected to this study.

CHRONIC URTICARIA